Source: Health Products Regulatory Authority (IE) Revision Year: 2022 Publisher: Glenwood GmbH, Pharmazeutische Erzeugnisse, Arabellastrasse 17, 81925 Munich, Germany
Catapres Ampoules 150 micrograms in 1 ml Solution for Injection.
| Pharmaceutical Form |
|---|
|
Solution for injection. Clear, colourless solution. |
Each 1 ml ampoule contains clonidine hydrochloride 150 micrograms.
For a full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Clonidine has been shown to have both central and peripheral sites of action. With long-term treatment clonidine reduces the responsiveness of peripheral vessels to vasoconstrictor and vasodilator substances and to sympathetic nerve stimulation. Early in treatment, however, blood pressure reduction is associated with a central reduction of sympathetic outflow and increased vagal tone. |
| List of Excipients |
|---|
|
Sodium chloride |
1 ml colourless glass (Ph. Eur. Type I) ampoules, marketed in packs of 5.
Glenwood GmbH, Pharmazeutische Erzeugnisse, Arabellastrasse 17, 81925 Munich, Germany
PA2256/002/001
Date of first authorisation: 01 April 1979
Date of last renewal: 01 November 2005
| Drug | Countries | |
|---|---|---|
| CATAPRES | Australia, Ireland, Japan, Malta, New Zealand, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.